All Articles

With record Q1 sales and key milestones for iDose® TR and Epioxa, all eyes are on Glaukos's July 29 financial release for its next growth chapter.

With AI-driven fraud costing billions, AT&T, T-Mobile, and Verizon are uniting behind a new weapon: network-based authentication, aiming to kill the SMS code.

As AI's energy thirst threatens to break the U.S. grid, a new deal sees energy giants building private gas power plants for data centers. It’s a race for power, but at what cost?

Four major accrediting agencies have unified their special education standards. This is a strategic play to create a global benchmark and remap the market.

As GLP-1 drugs surge in popularity, one company is betting on a new model for seniors that pairs prescriptions with strength training to fight muscle loss.

A Cambridge medtech firm has formed a global advisory board to fast-track its revolutionary 10-minute stroke test, a strategic move to disrupt pre-hospital care.

A private equity firm’s majority investment in services provider Smartlink reveals the real story: the gold rush is in the picks and shovels powering the digital world.

Children's apparel giant Carter's isn't just cleaning up its supply chain; it's building a strategic moat of consumer trust and long-term brand value.

With Natalie Hagstrom at the helm, the wellness brand signals a strategic pivot. We decode what this CPG-heavy leadership means for its future growth.

After 25 years, the influential Lucie and André Chagnon Foundation appoints its first independent Chair, a move signaling a major evolution in strategy.

At a UN forum in Geneva, a non-profit is urging global leaders to adopt blockchain as the essential foundation for trust and accountability in AI systems.

How the Danish liquorice maker leveraged a private equity buyout and a cult-like fan base to deliver 19% growth amid a global cocoa crisis.

A new partnership between STARCARES and B-LEAD 2026 is more than charity; it's a strategic move to cultivate talent and redefine corporate impact in Vietnam.

Calumet's $100M debt redemption is more than a fiscal cleanup; it's a calculated move to fuel innovation in renewable fuels and specialty chemicals.

Keenova Therapeutics' positive Phase 3 results for XIAFLEX could bring the first-ever approved drug for plantar fibromatosis, a painful, disabling condition.

Shoppers Drug Mart's new obesity program isn't just about weight loss; it's a strategic leap into primary care, challenging how we access healthcare.

Beyond record gold output, K92 Mining’s Q2 results reveal a strategic blueprint for growth, engineering prowess, and navigating geopolitical complexity.

Preclinical data shows GLIX1 can make PARP inhibitors effective in previously unresponsive tumors, a potential game-changer for 50% of ovarian cancer patients.

Evogene and Tel Aviv University are pairing generative AI with lab validation to bridge the 'valley of death' for academic drug research in Israel.

Bio-Techne's new AI-designed proteins tackle a critical hurdle in regenerative medicine: scalable manufacturing. This is how digital tools are industrializing biology.